RVMDW
Revolution Medicines, Inc.
Overview
Revolution Medicines, Inc.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
History
Earnings history
Reported quarters with consensus, surprise, and 1-day reaction context.
Track Record
SampleSpoken Alpha tracks RVMDW's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.83 | $2.37 | -22.9% | -7.3% | -6.9% |
| Q4 FY2026 | $2.06 | $2.37 | -13.1% | +2.2% | +2.3% |
| Q3 FY2026 | $1.91 | $2.45 | -22.1% | +3.6% | +2.3% |
| Q2 FY2026 | $1.96 | $2.51 | -22.1% | -4.9% | -4.7% |
| Q1 FY2025 | $1.97 | $2.64 | -25.3% | -1.1% | -3.6% |
| Q4 FY2025 | $2.33 | $2.67 | -12.9% | +2.0% | -0.7% |
| Q3 FY2025 | $2.20 | $2.71 | -18.7% | +3.9% | +2.2% |
| Q2 FY2025 | $2.16 | $2.60 | -16.8% | -7.3% | -6.1% |
| Q1 FY2024 | $2.38 | $2.77 | -14.1% | 0.0% | +0.2% |
| Q4 FY2024 | $2.23 | $2.66 | -16.1% | -3.8% | -1.9% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Jack AndersCFO7 mo20 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • guidance suspended Q1 FY2026
- Margaret A HornCOO6 mo2 callsCurrentSample
COO since 2025 • 3/4 beats (75%) • last guidance raise Q3 FY2026
- Alan B SandlerChief Development Officer3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • guidance suspended Q3 FY2026
- Lin WeiChief Medical Officer3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • last guidance cut Q3 FY2026
- Anthony ManciniSee Remarks3 mo4 callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • last call held guidance Q1 FY2026
- Xiaolin WangSee Remarks3 mono recorded callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • last call held guidance Q3 FY2026
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for RVMDW.
$ curl https://api.spokenalpha.com/v1/companies/RVMDWFAQ
Frequently asked about RVMDW
Where can I find Revolution Medicines, Inc.'s (RVMDW) earnings call transcripts?
Spoken Alpha indexes RVMDW's earnings call transcripts at https://spokenalpha.com/companies/RVMDW. Each call links to attributed speakers and parsed analyst Q&A. Revolution Medicines, Inc.'s own investor relations page is at https://ir.revmed.com/.